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Background With in vitro fertilization (IVF) techniques, only
20–25% of the transferred embryos lead to a pregnancy.
Objective To evaluate the beneficial effects of seminal plasma (SP)
or semen applied at the time of oocyte aspiration or embryo
transfer.
Search strategy Electronic databases were searched from their
inception up to August 2017.
Selection criteria We included all randomized controlled trials
(RCTs) evaluating the effects of SP or semen in IVF treatment.
Trials were considered if women were exposed to any kind of SP
or semen (either SP/semen injection or sexual intercourse) around
the time of oocyte pickup and embryo transfer.
Data collection and analysis The primary outcome was clinical
pregnancy rate (CPR).
Main results Eight RCTs on women undergoing IVF (2128 in
total) were included in the meta-analysis. Women randomized
in the intervention group had a significantly higher CPR
compared with controls (30.0 versus 25.1%; RR 1.20; 95% CI,
1.04–1.39). No significant differences were found in the
secondary outcomes, including livebirth rate, biochemical
pregnancy, miscarriage, multiple pregnancies, and birth weight.
The subgroup analyses (four RCTs, 780 participants), including
only those RCTs in which prepared undiluted SP was injected
just after oocyte pickup, conformed with the overall analysis for
the primary outcome (46.3 versus 37.2%; RR 1.23; 95% CI,
1.05–1.45).
Authors’ conclusion Because intravaginal or intracervical SP
application around the time of oocyte pickup is associated with
higher CPR, local application SP may be considered as a potential
treatment to improve implantation.
Keywords Fertility, ICSI, implantation, in vitro fertilization,
oocyte, seminal plasma.
Tweetable abstract SP at the time of oocyte pickup is associated
with higher CPR.
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Introduction
With in vitro fertilization (IVF) techniques, only 20–25% of
the transferred embryos lead to a pregnancy.1 Besides
embryo quality, endometrial receptivity plays an important
role in the establishment of a pregnancy.1,2 Around
implantation, a feto–maternal dialogue and a unique state
of maternal immune tolerance is needed to avoid an
immune attack on the implanting and developing
semi-allograft conceptus.2 This requires a well-balanced
activation and modulation of pro-inflammatory factors to
induce inflammatory pathways in the endometrium during
implantation. Endometrial function is highly sensitive to a
number of factors including supraphysiological concentra-
tions of estrogen in conventional gonadotropin-stimulated
IVF. Accordingly, several studies have revealed functional
alterations of the endometrium in IVF therapies, including
endometrial immune cell signaling.1–3




Seminal plasma (SP), fluid without sperm, has been
shown to stimulate the expression of pro-inflammatory
cytokines in vivo in animal studies and in humans
in vitro.1–5 SP and semen have therefore been suggested
to support implantation through their beneficial effects on
endometrial function and the maternal immune system.5
Several authors have suggested that SP application might
improve implantation in IVF therapies both because the
functionally advantageous sexual intercourse is typically
avoided around oocyte pickup, and hyperstimulation in
IVF therapies seems to negatively affect endometrial func-
tion.5 As SP application possibly compensates for these
negative effects, several clinical studies have been per-
formed. In these studies on gonadotropin-stimulated IVF
therapies, SP or semen was applied to the vagina or cer-
vix by intercourse or vaginal or cervical injection around
the time of follicle aspiration or embryo transfer to
improve the outcome. We conducted a systematic review
of randomized controlled trials (RCTs) using SP and
semen and performed a meta-analysis to summarize and




This review was performed according to a protocol
designed a priori and recommended for systematic reviews.
Electronic databases (MEDLINE, Scopus, ClinicalTrials.gov,
EMBASE, ScienceDirect, the Cochrane Library at the CEN-
TRAL Register of Controlled Trials, Scielo) were searched
from their inception up to August 2017. Search terms used
were the following: ‘seminal plasma’, ‘in vitro fertilization’,
‘pregnancy rate’, ‘labor’, ‘trial’, ‘randomized’, ‘review’,
‘study’, ‘live birth rate’, ‘IVF’, ‘endometrium’, ‘meta-analy-
sis’, ‘metaanalysis’, ‘implantation’, ‘ICSI’, ‘coitus’, ‘inter-
course’, ‘randomised’, ‘effectiveness’, ‘guidelines’, and
‘clinical trial’. No restrictions for language or geographic
location were applied. In addition, the reference lists of all
identified articles were examined to seek out studies not
captured by the electronic searches. The searches and the
eligibility of the studies were independently assessed by two
authors (GS, AC). Differences were discussed with a third
reviewer (ADS).
Study selection
We included all RCTs evaluating the effects of SP on out-
come during IVF treatment. Trials were considered if
women were exposed to any kind of SP or semen (either
SP/semen injection or sexual intercourse) at the time of
oocyte pickup and embryo transfer. Analyses included all
RCTs comparing the outcome of IVF treatment in women
exposed to SP or semen (i.e. intervention group) or not
exposed (either placebo or no treatment or abstinence) (i.e.
control group).
Quasi RCTs (i.e. trials in which allocation was done on
the basis of a pseudo-random sequence, e.g. odd/even hos-
pital number or date of birth, alternation) were excluded.
Risk of bias assessment
The risk of bias in each included study was assessed using
the criteria outlined in the Cochrane Handbook for System-
atic Reviews of Interventions. Seven domains related to risk
of bias were assessed in each included trial because there is
evidence that they are associated with biased estimates of
treatment effect: (1) random sequence generation; (2) allo-
cation concealment; (3) blinding of participants and per-
sonnel; (4) blinding of outcome assessment; (5) incomplete
outcome data; (6) selective reporting; and (7) other bias.
Review authors’ judgments were categorized as ‘low risk’,
‘high risk’, or ‘unclear risk’ of bias.
For this review, the GRADE approach was used to assess
the quality of the body of evidence relating to the primary
and secondary outcomes. The GRADEpro Guideline Devel-
opment Tool was used to import data from Review Man-
ager 5.3 (Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014) to create ‘Summary of find-
ings’ tables. A summary of the intervention effect and a
measure of quality for each of the above outcomes was
produced using the GRADE approach. The evidence can be
downgraded by one level from ‘high quality’ for serious (or
by two levels for very serious) limitations, depending on
assessments for risk of bias, indirectness of evidence, seri-
ous inconsistency, imprecision of effect estimates, or poten-
tial publication bias.
Outcomes
All analyses were done using an intention-to-treat
approach, evaluating women according to the treatment
group to which they were randomly allocated in the origi-
nal trials. The primary outcome was clinical pregnancy rate
(CPR) as defined by the original trial. Biochemical preg-
nancies were not included in the primary outcome.
Secondary outcomes were livebirth rate, biochemical
pregnancy rate, incidence of miscarriage and of multiple
pregnancy (including twin and higher order pregnancies),
and mean birth weight in grams.
Live birth was defined as any delivery of a live infant after
22 weeks of gestation. Biochemical pregnancy was defined
as positivity to hCG. Miscarriage was defined as pregnancy
loss before 22 weeks, using CPR as denominator.
A subgroup analysis of the primary outcome included
only those RCTs in which prepared undiluted SP was
injected into the vagina and/or cervix at the time oocyte
pickup was planned. We also performed subgroup analyses
on sperm-containing and sperm-void inseminations.
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Data analysis
Data analysis was completed by two authors independently
(GS, ADS) using Review Manager v. 5.3 (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
2014). The completed analyses were then compared, and
any differences resolved by discussion with a third reviewer
(AC).
Data from each eligible study were extracted without
modification onto custom-made data collection forms. A
two-by-two table was assessed for relative risk (RR); con-
tinuous outcomes means  SD were extracted and
imported into Review Manager.
Meta-analysis was performed using the random effects
model of DerSimonian and Laird to produce summary
treatment effects in terms of either a RR or a mean differ-
ence (MD) with a 95% confidence interval (CI). Hetero-
geneity was measured using I-squared (Higgins I2).
Potential publication biases were assessed statistically
using Begg’s and Egger’s tests.
The meta-analysis was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-Analyses
(PRISMA) statement.6 Before data extraction, the review
was registered with the PROSPERO international prospec-
tive register of systematic reviews (Prospero registration
number: 42016054354).
Results
Study selection and study characteristics
The flow of study identification is shown in Figure 1. Eight
RCTs on women undergoing IVF (2128 in total) were
identified as relevant and included in the meta-analysis.7–14
No quasi-randomized trials were identified. Publication
bias, assessed using Begg’s and Egger’s tests, was not signifi-
cant (P = 0.75 and 0.84, respectively).
All the included studies had ‘low risk’ of bias in ‘random
sequence generation’ and ‘performance bias’. Allocation
concealment was not adequate in all the trials (Figure 2).
The interventions varied: four studies analysed the effect
of prepared undiluted SP just after oocyte pickup; one
study analysed thawed diluted SP; two studies analysed the
effect of sexual intercourse around the time of oocyte aspi-
ration and/or embryo transfer; and one used untreated
diluted semen (Table S1).
In detail, the interventions included 0.5 ml of undiluted
SP in most of the included studies, while Aflatoonina
et al.11 used sexual intercourse as intervention at least once
12 hours after embryo transfer. Tremellen et al.12 was a
multicentre RCT including women who underwent IVF in
two centers. In centre 1 (Australia), intervention included
sexual intercourse at least once in a four-day period, from
two days before to two days after thawed embryo transfer.
In centre 2 (Spain), intervention included sexual
intercourse 12 hours before and 12 hours after fresh
embryo transfer. All data from both centres were used for
this meta-analysis. As control, four trials used 0.5 ml of
placebo (sodium chloride solution), two used no insemina-
tion, and two used abstinence from sexual intercourse. All
RCTs used progesterone for both groups (Table S1).
Figure 1. Flow diagram of studies identified in the systematic review.
[Prisma template (Preferred Reporting Item for Systematic Reviews and
Meta-analyses)].
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All trials included couples with an aetiology of infertility
(e.g. male factor, tubal factor, mixed factors, unexplained
infertility) (Table S2).
Synthesis of results
Table S3 shows the primary and secondary outcomes of the
meta-analysis. Women randomized in the intervention
group had a significantly higher CPR compared with con-
trols (30.0% versus 25.1%; RR 1.20; 95% CI, 1.04–1.39;
Figure 3). No significant differences were found in the sec-
ondary outcomes.
The subgroup analyses (four RCTs, 780 participants)
including only those RCTs in which prepared undiluted SP
was injected just after oocyte pickup were in agreement
with the overall analysis for the primary outcome (RR 1.23;
95% CI, 1.05–1.45; Figure 4).
The subgroup analyses of sperm-containing and sperm-
void inseminations both accord with the overall analysis
for the primary outcome (RR 1.20; 95%, CI 1.09–1.72; and
RR 1.26; 95% CI, 1.08–1.66, respectively)
The quality of evidence was downgraded because of seri-
ous ‘imprecision’ in the secondary outcomes. Outcomes
were imprecise because studies included relatively few
patients and few events and therefore had wide CIs around
the estimates of the effect and because the optimal
information size was not reached. The quality of the evi-
dence was also downgraded another level because of serious
‘indirectness’ that was due to differences in the interven-
tions for both primary and secondary outcomes.
Discussion
Main findings
This meta-analysis from eight RCTs on women undergoing
IVF (2128 in total) showed that SP or semen application
near the time of oocyte pick up (OPU) was associated with
higher CPR. Most data come from RCTs using 0.5 ml of
undiluted SP injected into the vaginal vault or cervical
canal after OPU.
Strengths and limitations
Our study has several strengths: the eight trials included had a
low risk of allocation bias based on a Cochrane Collaboration
tool assessment; intent-to-treat analysis was used; and statisti-
cal analysis showed that publication bias was not apparent.
These are key elements that are needed to evaluate the reliabil-
ity of a meta-analysis. To our knowledge, no prior meta-analy-
sis on this issue is as large, up-to-date, or comprehensive.
Limitations of our study are mostly inherent in the
limitations of the included studies. Only four studies
Figure 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial. Plus sign, low risk of bias; minus sign, high risk of bias; question
mark, unclear risk of bias. (B) Risks of bias presented as percentages across all included studies.
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used a placebo as control and were double blind. We
acknowledge that some outcomes were underpowered,
but those were uncommon outcomes (e.g. miscarriage,
multiple pregnancy) with an estimated overall rate of
<10%. The major shortcomings of this meta-analysis lie
in the differences in the intervention protocols used and
the different definitions of CPR. The observed effect may
be based on endometrial factors and not simply exposure
to SP. The definition of clinical pregnancy was also dif-
ferent between the trials. Finally, there was a lack of core
outcome sets which affects infertility research owing to a
lack of standardization of study outcomes. The timing of
insemination as well as unknown or unmeasured factors
not reported in publications could have modified the
observed associations. While we did not include as-per-
protocol biochemical pregnancies in the primary outcome
(i.e. CPR), one trial did not specify if biochemical preg-
nancies were included in the total numbers reported for
CPR.
Interpretation
This review included different interventions, including dif-
ferent SP application at the time of oocyte pick up. So far,
this analysis only allows us to judge the effect of any kind of
SP or semen exposure. To analyse if SP may be used as a
therapy in conventional gonadotropin-stimulated IVF,
subgroup analyses according to type of intervention have
been assessed.15,16
As assessed by GRADE, the quality level of summary esti-
mates was moderate for the primary outcome and low for the
secondary outcomes, indicating that the true effect may or is
likely to be substantially different from the estimated effect.
Our study was in agreement with a prior review.16 Craw-
ford et al., in a meta-analysis of seven RCTs, found signifi-
cantly improved outcomes when women were exposed to
SP around the time of ovum pickup or embryo transfer.
Our review included more RCTs and more randomized
women, however. We also obtained additional unpublished
data and performed subgroup analyses.
Conclusion
SP may be able to stimulate the expression of pro-inflam-
matory cytokines in vitro like interleukin (interleukin-1b)
and leukaemia inhibiting factor. A few studies have shown
that endometrial immune response to SP antigens could
activate inflammatory pathways that may have a positive
effect on the implantation rate.2–4 Our review, based on 8
RCTs, shows a statistically significant increase in CPR in
women who were exposed to SP during their IVF cycle.
These findings could add value to the role of SP in women
undergoing IVF.
Figure 3. Forest plot of clinical pregnancy rates in the overall analysis. CI, confidence interval.
Figure 4. Forest plot of clinical pregnancy rates in trials using only prepared undiluted seminal plasma injected immediately after oocyte pickup. CI,
confidence interval.
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In summary, based on these level-1 data, there is a signifi-
cant association of a higher CPR not only with all kinds of SP
and semen applications around the time of oocyte pickup and
embryo transfer, but also specifically with intravaginal and
intracervical injection of prepared undiluted SP exactly at
the time of oocyte pickup. These findings support the
hypothesis that SP has a positive effect on endometrial
function and the maternal immune system, thereby support-
ing implantation. Furthermore it suggests SP application as
a potential therapeutic tool to improve implantation in IVF
therapy. However, as secondary outcomes, including live
birth and miscarriage, were not statistically different, further
studies need to be undertaken to better understand whether
and under what circumstances the use of SP injection near
the time of OPU translates into better clinical outcomes.
Future trials should report on all pertinent pregnancy out-
comes and include cost-effectiveness analyses. Most impor-
tantly, future studies should include a clear protocol (e.g.
progesterone, intravaginal, or intracervical injection), so they
may be easily evaluated and replicated.
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